Status:
UNKNOWN
University of Washington Alzheimer's Disease Research Center (UW ADRC) Imaging & Biomarker Core
Lead Sponsor:
University of Washington
Collaborating Sponsors:
National Institute on Aging (NIA)
Ellison Foundation
Conditions:
Alzheimer Disease
Eligibility:
All Genders
55+ years
Brief Summary
This is a cross-sectional, observational study that characterizes research participants with Alzheimer's disease (AD) for their patterns of brain degeneration with the investigational tau positron emi...
Detailed Description
Memory loss and dementia, including Alzheimer's disease (AD), are heterogeneous in terms of pattern of symptoms and brain atrophy, likely due to underlying variability in AD biological processes, as w...
Eligibility Criteria
Inclusion
- Amnestic MCI or Amnestic multimodal MCI or dementia primarily attributed to AD, by consensus diagnosis in the ADRC Clinical Core;
- Evidence of A+ T+ Alzheimer disease by CSF evaluation (e.g. low amyloid beta(AB)42 or 42/40 ratio and elevated p-181-tau); or evidence of A+ Alzheimer disease by amyloid PET.
- Age of presentation for first evaluation \> 55 years;
- Sporadic onset, defined by not from a known autosomal dominant AD family and not more than 1 first degree relative with dementia onset before age 65;
- Clinical Dementia Rating scale (CDR) score 0.5 or 1.0;
- English competency sufficient to complete cognitive testing battery to the satisfaction of ADRC neuropsychologist;
- MRI scan in the Clinical Core, with additional selection for topographic diversity, based on the MRI imaging.
Exclusion
- History of symptomatic cerebrovascular disease (CVD) or CVD evaluated to contribute significantly to cognitive impairments;
- Parkinsonism, or meeting revised McKeith criteria for possible or probable Dementia with Lewy bodies;
- Contraindication to MRI scanning (e.g. metal implants, severe claustrophobia);
- Premorbid history of neurologic disease that may contribute to cognitive impairment (e.g. multiple sclerosis, epilepsy, brain tumor);
- History of developmental dyslexia or other developmental disorder affecting validity of cognitive tests. These exclusion criteria minimize comorbidity;
- Pregnancy or breast-feeding.
Key Trial Info
Start Date :
November 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2025
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04437290
Start Date
November 1 2022
End Date
April 30 2025
Last Update
November 2 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.